« AART »

Etude de l’efficacité et de la tolérance de la suspension d’acétate d’anecortave (Retaane®) en injection juxtasclérale postérieure, comparée à une injection « fantôme », en prévention de la néovascularisation choroïdienne due à la DMLA

Alcon Terminates The Development Of Anecortave Acetate In Age-Related Macular Degeneration
Article Date: 14 Jul 2008 - 2:00 PDT
Alcon, Inc. (NYSE:ACL) announced today it has terminated the development program designed to evaluate the benefit of anecortave acetate treatment on the risk for developing sight-threatening choroidal neovascularization secondary to age-related macular degeneration. The decision followed a planned interim analysis of studies C-02-60 A and B that was performed after 2,546 patients had completed the 24 month time point. In this analysis, anecortave acetate showed no effect on the primary or secondary endpoints. In addition to terminating studies C-02-60 A and B, the company also terminated two smaller studies with an identical design that were being conducted in Asia, C-04-30 and C-05-34.